ReviewCurrent rheumatology reviews2025
Vaccine to Nano-Vaccine: Novel Technique to Treat Rheumatoid Arthritis.
Review in Current rheumatology reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Autoimmune diseases are a class of diseases wherein the immune system of the body targets itself through autoreactive T cells and autoantibodies. Autoimmune diseases are classified as organ-specific autoimmune diseases and systemic autoimmune diseases. Organ-specific autoimmune diseases such as primary biliary cirrhosis, Hashimoto's Thyroiditis (HT), Type 1 Diabetes mellitus (T1D), and Graves' Disease (GD) are characterized by a unique immune system response to autoantigens in a single organ. Systemic autoimmune diseases such as Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjogren syndrome are characterized by a systemic spread of autoantigens causing a multi-organ attack. In this review, we discuss rheumatoid arthritis, its prevalence in India, and its risk factors. We discuss the pharmacotherapies for RA that are currently available on the market. By identifying the disadvantages and side effects of the treatment, we mainly focus on how nanotechnology will be helpful in vaccine research and the advancement of anti-RA therapeutics from vaccines to nano-vaccines. In addition, the benefits of nano-vaccines are explored in future perspectives. In conclusion, nano-vaccines will be a novel technique for treating RA because they show possible outcomes from nanovaccine use.
Indexed as
Identifiers
40070336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.